Vaxart, INC Form 4 insider transactions

Director W. Mark Watson reported the acquisition of 16,000 common stock shares and an option to purchase 95,400 shares of Vaxart, Inc.

Director Robert A. Yedid reports acquisition of Vaxart shares and stock options.

Sean Tucker, SVP and Chief Scientific Officer of Vaxart, files an amendment to a previous Form 4 to correct an administrative error regarding the reporting of beneficially owned securities.

Sean Tucker, SVP and Chief Scientific Officer of Vaxart, Inc., reports changes in beneficial ownership of company stock due to tax withholding upon RSU vesting.

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports the disposal of 3,292 shares of common stock to cover income tax obligations related to vested RSUs.

Sean Tucker, SVP, Chief Scientific Officer of Vaxart, Inc., reports acquisition and disposal of common stock and stock options.

Phillip E. Lee, CFO of Vaxart, Inc., reports the acquisition and disposal of company stock and stock options due to tax obligations and vesting of restricted stock units.

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports transactions involving company stock, including acquisitions, disposals, and stock option grants.

Edward Berg, SVP and General Counsel of Vaxart, Inc., reports transactions involving Vaxart common stock, including the withholding of shares for tax obligations and the grant of restricted stock units and stock options.

Vaxart's CEO, Steven Lo, was granted 250,000 shares of common stock and options to purchase 1,000,000 shares on March 18, 2024.